British drug company Antisoma reported today that it has picked up Cambridge, MA-based Xanthus Pharmaceuticals for about $52 million in shares. Xanthus focuses on therapies for cancer and autoimmune diseases and has five drugs in clinical development. One of them is an oral cancer drug that is already marketed outside the U.S. by Bayer-Schering Pharma.
